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This review covers recent literature on the lamellarins, a family of marine natural products, and 
related analogs, encompassing synthetic strategies for total synthesis, structure-activity 
relationships (SAR), and studies on mechanisms of biological action, namely in the context of anti-
tumor activity. It reviews work published from January 2008 to December 2010.  
Introduction  10 
Lamellarin D (Lam-D, Fig. 1), which comes from a large 
family of marine pyrrole alkaloids, is currently in preclinical 
development as an  anti-cancer drug. Comprehensive reviews 
of this compound were published in 2007 and 2008.1, 2 
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Fig. 1 Structure of Lam-D 
 Recent advances in the pharmacological development of 
Lam-D include the identification of new cellular targets of 
this compound and new insights into its mechanism of action. 
The malate–aspartate shuttle was recently identified as a new 20 
target for Lam-D by proton NMR-based metabolomics,3 and 
certain protein kinases relevant to cancer have recently been 
reported as targets of Lam-D, Lam-N and other lamellarins.4 
Lam-D exerts its anti-tumor activity through complementary 
pathways: a nuclear route via topoisomerase I (Topo I) 25 
inhibition,5,6 and mitochondrial targeting by induction of 
mitochondrial permeability transition (MPT).7  
 Robust synthesis of Lam-D has enabled SAR and 
mechanism of action studies. Thus, the vast chemical space of 
the Lam structure has been explored through modified 30 
analogs, including 1-dearyl,8 2-dearyl,9 lactone-free 
derivatives,10 lactam,11 and polymeric and peptidic nuclear 
location signal conjugates.12, 13 
 Herein, in addition to the recent synthetic strategies 
developed for total synthesis of Lam-D and its numerous 35 
naturally occurring and synthetic analogs, recent work on 
SAR studies and on using multi-target mechanisms to induce 
apoptosis are also discussed. 
1. Synthesis of Lamellarins 
1.a. Construction of the pyrrole core 40 
Numerous synthetic strategies based on the formation of the 
five-membered pyrrole heterocycle have been developed for 
the pentacyclic core of the Lamellarins (Fig. 2).  
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Fig. 2 Synthesis of lamellarins based on construction of the pyrrole core  45 
 A new protocol for the construction of the Lamellarin 
scaffold 2 (Fig. 2 R1-R6 = H) relies on Pd-catalyzed 
intramolecular hydroamination of the acetylenic 
aminocoumarin derivative 1.14 This procedure has not yet 
been exploited in natural product synthesis.  50 
 The key step in a recent synthesis of Lam-G trimethyl 
ether15 is the final step: haloarylation of 3-bromo-4-(3,4-
dimethoxybenzoyl)-6,7-dimethoxy-chroman-2-one 3 with 6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
(Scheme 1). 55 
 
Scheme 1 Key step in the synthesis of Lam-G trimethyl ether15 
 This journal is © The Royal Society of Chemistry 2011 Med. Chem. Commun. 
 1-Benzyl-3,4-dihydroisoquinolines have been transformed 
to Lam-G trimethyl ether and Lam-U using short reaction 
sequences. Grob reaction of dihydroisoquinoline 4 with the 
nitrocinnamate 5 afforded pyrroles 6a and 6b.16 Subsequent 
O-debenzylation and lactonization provided the 5 
aforementioned natural product, plus Lam-U (Scheme 2).  
 
Scheme 2 Synthesis of Lam-G trimethyl ether and Lam-U16 
 Gupton et al.17 reported formal syntheses of Lam-G 
trimethyl ether and ningalin B via formation of the 10 
polysubstituted pyrrole derivatives 7a and 7b, respectively, 
from a vinylogous iminium salt derivative. Subsequent 
transformations of these highly substituted pyrroles enabled 
efficient regio-controlled formal syntheses of the targets 
(Scheme 3). 15 
 In late 2010 Li et al. reported a new, concise synthesis of 
Lam-D and Lam-H by condensation of 3-isopropoxy-4-
methoxyphenethylamine with two units of the corresponding 
phenethylaldehyde derivative, followed by AgOAc-mediated 
oxidative coupling to construct the pyrrole core. Their 20 
synthesis featured two additional induced oxidative 
cyclizations to form the lactone and the pyrrole−arene C-C 
bond. Thus, Lam-D and Lam-H were prepared in seven steps 
and in overall yields of 17% and 16%, respectively (Scheme 
4).18 25 
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Scheme 4 Synthesis of Lam-D and Lam-H18 
1.b. Cross-coupling reactions  
Efforts towards Lamellarin synthesis have vastly benefited 30 
from Pd(0) catalyzed cross-coupling chemistry—namely, the 
Heck, Negishi and Suzuki reactions. Recently reported 
methodologies for these compounds using this chemistry are 
described below.  
 Total syntheses of Lam-O, P, Q, and R have been achieved 35 
by using as key synthetic steps the Pd-catalyzed Suzuki–
Miyaura cross-coupling reaction of N-benzenesulfonyl-3,4-
dibromopyrrole (8) with an arylboronic acid followed by 
directed α-lithiation.19 N-Deprotection and substitution gave 
the natural products (Scheme 5). 40 
 
Scheme 5 Synthesis of lamellarins O, P, Q, and R19 
 
Scheme 3 Formal syntheses of Lam-G trimethyl ether and ningalin B17 
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Scheme 6 Synthesis of Lam-α 13-, 20-sulfate, and 13,20-disulfate20,21
 Sequential Suzuki-Miyaura coupling of 3,4-5 
dihydroxypyrrole bistriflate (9) as a key reaction20, 21 was 
harnessed to prepare three Lam-α sulfate derivatives: Lam-α 
13-sulfate, 20-sulfate, and 13,20-disulfate. The common 
intermediate 10, in which 13-OH and 20-OH are protected 
with orthogonal protecting groups, was the shared precursor 10 
(Scheme 6).  
 A general method for the synthesis of N-unsubstituted 3,4-
diarylpyrrole-2,5-dicarboxylates also has been developed.22 
The principal reactions comprised a Hinsberg-type synthesis 
of dimethyl N-benzyl-3,4-dihydroxypyrrole-2,5-dicarboxylate 15 
followed by palladium-catalyzed Suzuki-Miyaura coupling of 
its bis-triflate derivative. The N-benzyl protecting group of 
the resulting 3,4-diarylpyrrole-2,5-dicarboxylates was cleanly 
removed under hydrogenolysis or solvolysis. The authors 
observed that the regioselectivity of the Suzuki cross-coupling 20 
of dihalopyrrole esters was influenced by the reaction 
solvent.23 
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Scheme 7 Synthesis of Lam-S24 
 Banwell et al.24 recently published the first total synthesis 25 
of Lam-S and a new synthesis for Lam-G trimethyl ether, 
based on the same strategy. Their route included two 
sequential Suzuki–Miyaura cross-coupling reactions to insert 
the two polyalcoxyaryl groups at positions 3 and 4 of the 
pyrrole derivative 11. The resulting compound was then 30 
subjected to decarboxylative Heck cyclization and, in the case 
of Lam-S, subsequent O-iPr ether deprotection. (Scheme 7). 
 
1.c. Lactone-free Lam-D analogs, and azalamellarins 
Hu et al. reported their work on developing 1,2-diphenyl-5,6-35 
dihydropyrrolo[2,1-a]isoquinolines 13 as hybrids of 
combretastatin A4 and Lam-D with the aim of retaining the 
cytotoxic and anti-mitotic activities of the parent compounds 
(Scheme 8).10 They exploited a previously described strategy 
for N-ylide-mediate pyrrole formation which involves 40 
dihydroisoquinoline hydrochlorides and phenacyl bromides 
(see Scheme 1). Their work complements, and is closely 
related with, the preparation of a library of open-chain 
analogs that had been reported a few years earlier.9  
 45 
Scheme 8 Synthesis of combretastatin A4 and Lam-D hybrid-library 10 
 
 Thasana et al. obtained a library of seventeen 
azalamellarins using microwave-assisted CuI-mediated C-N 
bond formation.11  50 
1.d. 1- and 2-Dearyl Lam-D analogs  
Iwao et. al. synthesized numerous Lam-D analogs (the 1-dearyl-
Lam compounds 14; Scheme 9)8 using a methodology that they 
had previously developed.19 
 This journal is © The Royal Society of Chemistry 2011 Med. Chem. Commun. 
 
Scheme 9 Synthesis of 1-dearyl-Lam-D analogs8 
 
 Given the results of SAR studies on similar 2-dearyl 
analogs,9 the aforementioned compounds created by the Iwao 5 
group should prove interesting for biological evaluation. 
1.e Polyethylene glycol (PEG), dendrimeric, and nuclear 
location signal (NLS) bioconjugates of Lam-D 
Mono- and di-PEG bioconjugates of Lam-D (15a & 15b, and 
16, respectively) with improved solubility have been prepared 10 
from the corresponding partially protected (O-iPr or O-Bn) 
phenolic derivatives 17a-c; alternatively, tri-PEG conjugates 
(18) have been obtained directly from the parent Lam-D 
compound (Scheme 10).12 A strategy similar to that described 
for the total synthesis of Lam-D25 was exploited to prepare 15 
19a-c  precursors of 15a,b and 16 (Scheme 10). 
 
In the synthesis of the dendrimeric- and NLS-Lam-D 
bioconjugates 20 and 21, the amino and guanidino groups of 
the oligomeric building blocks were protected with N-Boc.13 20 
The PEG-based dendrimer 22 was condensed with protected 
Lam-D 23 using EDC·HCl and DMAP as coupling agents. 
Simultaneous removal of the Boc and TBDPS-protecting 
groups with HF at low temperature afforded 20 (Scheme 11). 
 Pre-activation of the Boc-protected NLS-peptide 24 with 25 
N,N,N’,N’- tetramethylchloroformamidinium hexafluorophos-
phate (TCFH) and NEt3, followed by the addition of a solution 
the Boc-protected Lam-D 25 and DMAP, were required to 
form the bioconjugates, which was obtained in 45% yield. 
Elimination of the nine Boc protecting groups with 40% TFA 30 
in CH2Cl2 gave compound 21 in 17% yield (Scheme 11). 
2. Molecular Structure-Activity Determinants, 
and SAR Studies 
Natural products remain an underutilized source of leads for 
the pharmaceutical industry.26 Preparing analogs of these 35 
products through medicinal chemistry approaches to explore 
maximum chemical space is a valuable method for improving 
and/or modulating the parent biological activity. Given their 
diverse anti-tumor activities, lamellarins have been the subject 
of several SAR studies in recent years.  40 
  Hu et al. prepared a library of structurally simplified lactone-
free lamellarin (LF-Lam) analogs having a 1,2-diphenyl-5,6-
dihydropyrrolo[2,1-a]isoquinoline core structure. This library 
was partially inspired by the close structural resemblance
 45 
Scheme 10 Synthesis of mono-, di- and tri-PEG-bioconjugates of Lam-D12 
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Scheme 11 Preparation of dendrimeric- and NLS-bioconjugates of Lam-D13
between Lam-D and combretastatin A4, which contains a 
conserved cis-stilbene motif. They evaluated twenty-two 5 
novel, diversely-substituted analogs, which they then screened 
for anti-proliferative activities against five cancer cell lines. 
The compounds generally showed poor activity (sub-
millimolar IC50 values); the most active of them are shown in 
Fig. 3 and listed in Table 1.  10 
 
Table 1 Anti-proliferative activities of the three best LF-Lam analogs 
prepared by Hu et al. 10 
Compound IC50 (µM) 
A549 K-
562 
SMM-
7721 
SGC-
7901 
HCT-
116 
LF-Lam 1 > 
94.1 
4 > 94.1 > 94.1 1.4 
LF-Lam 2 6.7 2.7 10.9 11.4 0.7 
LF-Lam 3 23.3 5.3 15 22.7 13.8 
 
Cell lines: A549, human non-small-cell lung carcinoma; HCT-116, 
human colon carcinoma; K-562, human erythromyeloblastoid 15 
leukemia; SGC-7901, human gastric adenocarcinoma; SMM-7721, 
human hepatocarcinoma. 
 
Nevertheless, we believe these results reflect a partial but 
promising structural simplification. Selective removal of the 20 
O-iPr groups would easily afford the corresponding free 
phenolic groups at positions C8 and C4’, which are crucial for 
the activity of open-chain methyl ester lamellarin analogs.9 
The Hu group’s results are in agreement with previous 
findings related to the presence of the OH at C4” of the aryl at 25 
position 2 of the pyrrolo[2,1-a]isoquinoline, which are also 
crucial role for activity. 
 
Fig. 3 Structures of combretastatin A4 and LF-Lam analogs10
30 
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 Ruchirawat et al. extensively assessed the cytotoxic 
activities of 25 lamellarins against multiple cancer cell lines 
derived from six different cancer types (oral, lung, breast, 
liver, cervix, and blood cell).27 The compounds comprised 22 
naturally occurring lamellarins and three synthetic derivatives 5 
containing either a saturated or an unsaturated C8-C9 bond, 
and bearing different OMe, OH and H substitution patterns on 
the aryl rings. Their SAR studies were the first to reveal the 
importance of having an OH group at C10 for biological 
activity and also confirmed prior findings1,2 that the C8=C9 10 
double bond increases cytotoxicity; that the OH groups at C3 
and C11 are crucial to activity; and that methylation of the 
OH groups at C12, C3’ and C4’ induces only subtle changes 
in the GI50 values.27  
 Lamellarins-D, -X, -ε, -M, -N, and dehydro-Lam-J were the 15 
most potent anti-tumor compounds of the family (Fig. 4): they 
had IC50 values ranging from sub-nanomolar (0.08 nM) to 
micromolar (3.2 µM).27 Furthermore, they showed selectivity 
against cancer cells: these lamellarins were roughly 3 to 
1,000,000 times more toxic to cancer cells from all eleven cell 20 
lines tested than to the control (normal) cells, MRC-5 human 
embryonic lung fibroblasts (Table 2).27 In related work, Lam-
D and its bioconjugates were similarly selective for cancer 
cells over BJ skin fibroblasts.12, 13  
Hannongbua et al. have studied lamellarins using receptor-25 
independent (RI) 4D quantitative SAR (QSAR) models.28, 29 
They obtained valuable 3D pharmacophore information from 
a set of 25 structurally complex lamellarins screened in silico 
against human hormone dependent T47D breast cancer cells. 
Overall, they identified formation of an intermolecular 30 
hydrogen bond, and the hydrophobic interactions of 
substituents at C10, C11 and C12, as the most important 
features for cytotoxicity against the cancer cells. 
  
Fig. 4 Structures of aza-Lam-D; dehydro-Lam-J; and Lam-X, -ε, 35 
-M and -N27, 11 
They also suggested that hydrophobic substitutions at C3’ and 
C4’ could enhance cytotoxicity.  
 Ruchirawat et al. prepared Lam-D analogs containing a 
lactam rather than a lactone. Their work was the first report of 40 
a SAR studies done for a change at this position.11 The 
resulting azalamellarins were screened against four cancer cell 
lines (HuCCA-1, A-549, HepG2, and MOLT-3). Aza-Lam-D 
showed good activity (IC50 values in the micromolar range), 
comparable to that of its parent, Lam-D (Table 2). The amide 45 
N-H confers the aza-analogs with greater solubility in 
biological media compared to that of the parent compound. 
Interestingly, N-alkylated aza-analogs were not as potent as 
the parent compound.  
For pharmacological enhancement through optimized use of 50 
chemical space, the Ruchirawat group suggested introducing
Table 2 Cytotoxicity of Lam-D; aza-Lam-D; dehydro-Lam-J; and Lam-X, -ε, -M and -N27, 11 
Comp. IC50 (µM) 
Oral Lung Breast Liver C rvi
x 
Blood cell Leuke
mia 
Fibroblast 
KB A549 H69
AR 
T47D MDA
-MB-
231 
HuCC
A-1 
HepG
2 
S10
2 
HeLa P38
8 
HL-
60 
MOL
T-3 
MRC-5 
Lam-D 
 
0.04 0.06 0.4 0.00008 0.4 0.08 0.02 3.2 0.06 0.1 0.04 0.049 9.2 
Aza-
Lam-D 
NR 0.74 NR NR NR 0.12 0.13 NR NR NR NR 0.03 NR 
Dehydro
-Lam-J 
0.08 0.04 0.3 0.0001 0.4 0.006 0.01 2.1 0.08 0.08 0.04 NR > 97.4 
Lam-M 0.2 0.04 0.3 0.009 0.1 0.06 0.02 1.9 0.3 0.1 0.06 NR 13.4 
Lam-N 0.06 0.04 0.06 0.0006 0.6 0.008 0.02 2.3 0.04 0.08 0.04 NR > 100.1 
Lam-X 0.08 0.3 0.3 0.006 0.08 0.04 0.2 1.6 0.09 0.3 0.2 NR 10.1 
Lam-ε 
 
0.3 0.3 2.3 0.006 0.3 0.07 0.1 2.1 0.3 0.3 0.1 NR 25.8 
 
NR: not reported; Cell lines: A549, human non-small-cell lung carcinoma; H69AR, human multi-drug-resistant small-cell lung carcinoma; HeLa, human 
cervical adenocarcinoma; HepG2, human hepatocellular carcinoma; HL-60, human promyelocytic leukemia; HuCCA-1, human cholangiocarcinoma; KB, 
human oral epidermoid carcinoma; MDA-MB-231, human hormone-independent breast cancer 231; MOLT-3, T-lymphoblast (acute lymphoblastic 55 
leukemia); MRC-5, human fetal/embryonic lung fibroblast; P388, mouse lymphoid neoplasm; S102, human hepatocellular carcinoma; T47D, human 
hormone-dependent breast cancer. 
 This journal is © The Royal Society of Chemistry 2011 Med. Chem. Commun. 
additional polar functionalities (e.g. alternative H-bond 
donors, acceptors, and ionizable groups) into this family of 
compounds.30 
 Biopolymeric mono-, di- and tri-ester conjugates of Lam-D 
(at its phenolic sites) are more soluble than the parent 5 
compound and can be readily hydrolyzed in physiologic 
conditions.12 For example, the monoPEG 15a is up to 80-
times more soluble in water than Lam-D. Moreover, a release 
of up to 97% of Lam-D has been achieved by incubation of 
15a for 6 h at 37 °C in Dubelcco’s modified Eagle’s medium 10 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 
and 100 units/mL penicillin and streptomycin.13 The 
cytotoxicity of the bioconjugates 15, 16, 18, 20 and 21 was 
assessed against three human tumor cell lines (MDA-MB-231 
breast, A-549 lung and HT-29 colon). Several compounds 15 
exhibited greater cellular internalization than did Lam-D, and 
more than 85% of the bioconjugates showed a lower GI50 than 
did Lam-D.12,13 Cellular internalization was analyzed, and a 
nuclear distribution pattern was observed for bioconjugate 21, 
which contains an NLS.13 The mechanisms of action for Lam-20 
D and these derivatives have been indentified as cell cycle 
arrest at G2 phase and apoptotic cell-death pathways.12  
 In summary, the various SAR studies and virtual screening 
models for lamellarins and related analogs discussed above 
have demonstrated the efficacy of targeted medicinal 25 
chemistry. The findings from this work may contribute to 
future drug development of synthetic analogs and to the 
selection of synthetic scaffolds. 
3. Activities and Mechanism of Action of Lam-D 
Topo I is a nuclear target of Lam-D 30 
Inhibition of the nuclear DNA relaxation enzyme 
Topoisomerase I (Topo I) by Lam-D has recently been 
characterized in a model system of highly nicked double-
stranded DNA (dsDNA) by using optical tweezers force-
stretching experiments (Fig. 5a). In these experiments, normal 35 
Topo I activity—which ultimately leads to total repair of the 
DNA nicks—is shown by a higher force plateau in DNA 
stretching-relaxation plots and complete disappearance of the 
overstretching hysteresis (Figs. 5b and 5c, green curves). 
When Lam-D is added to the system, it prevents the religation 40 
step and blocks enzyme turnover, as seen by the absence of a 
higher force plateau and by a large, non-vanishing hysteresis 
between the stretching and relaxing paths of the force cycle 
(Figure 5d, green curve).6 
 45 
“insert Figure 5 here” 
Fig. 5 Optical tweezers (OT) force assay of Topoisomerase I (Topo I) activity. (a) Schematic of the experiments, in which each 3’ biotinylated end of the 
dsDNA is attached to one streptavidin-coated bead. (b-d) OT Force-DNA extension measurements. b) Force-stretching experiment starting from a 
dsλDNA molecule with a few nicks, as indicated by the small hysteresis area (black curve). Stretching-relaxing cycles are indicated by half-bold half-thin 
plots. The cleavage activity of Topo I after 9 min of reaction generated an ssDNA-like domain, a heavily nicked dsDNA which exhibited the mechanical 50 
properties of ssDNA (red curve). After a further 11 min the ligating activity of Topo I removed the ssDNA-like domain (green curve). c) Force-stretching 
experiment starting with highly-nicked dsDNA, as indicated by the large hysteresis area (black curve). Topo I activity is reflected by a higher-level 
plateau, which indicates total religation of the initial DNA nicks, and by complete disappearance of the overstretching hysteresis (green curve, 18 min 
reaction time). The arrow indicates a drop in the stretching curve resulting from Topo I cleavage during the cycle. d) Force assay of Topo I activity in the 
presence of Lam-D. Starting λDNA exhibited a small hysteresis area (black curve) corresponding to a dsDNA molecule with only a few nicks. The 55 
cleavage activity of Topo I induced a large increase in hysteresis in the presence of Lam-D after the first two minutes of reaction (red curve). Stabilization 
by Lam-D of this intermediate complex resulted in inhibition of the religating activity of Topo I (green curve, acquired at 21 min reaction).6, 31 
 
  
60 
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Inhibition of Topo I by Lam-D has also been demonstrated by 
atomic force microscopy (AFM) imaging of plectonemic DNA 
molecules with Topo I enzyme attachments that were treated 
with a combination of Lam-D and a reaction buffer used to 
relax supercoiled DNA (see Fig. 6).6  5 
“insert Figure 6 here” 
Fig. 6 AFM imaging of Topo I-treated plasmid DNA. a) Supercoiled 
circular DNA treated by Topo I in the presence of Lam-D. Horizontal 
scale is 0.75 µm, vertical scale is 2 nm for all images. b) Interpretive 
illustration. The green dots represent Topo molecules.6, 31 10 
 Nuclear penetration remains a challenge in the 
pharmacological development of Lam-D and related 
compounds. Albeit the aforementioned work elegantly 
demonstrates how Lam-D blocks the nuclear enzyme Topo I, 
if the drug cannot reach the nucleus, then this activity is 15 
useless. Confocal microscopy experiments on internalization 
of Lam-D and its PEG conjugates 15, 16 and 18 in three 
different cell lines show that these compounds chiefly end up 
in the cytoplasm12, although Lam-D and the PEG-NH2 
compound
 
15a were able to weakly reach the nucleus in one 20 
of the tested cell cultures. Chemical bioconjugation of Lam-D 
to a nuclear localization signal (NLS) peptide to give the 
Lam-D NLS bioconjugate 21 was explored as a strategy to 
enable active transport of the drug through the nuclear 
membrane. Experiments on the co-localization  and cellular 25 
distribution of Lam-D NLS bioconjugate in three green 
fluorescent protein-Topo I (GFP-Topo I) transfected cell 
cultures (HT-29, A-549, and MDA-MD-231 cell lines), 
indicated that it localized to the nucleus in HT-29 and A-549 
cells, while GFP-Topo I was located in the nucleus for all 30 
three cell types. Thus, the NLS peptidic sequence is at least 
partly responsible for nuclear import of 21 in those cell lines. 
The authors concluded that greater cytotoxicity correlated 
with greater nuclear localization.13 
Induction of mitochondrial apoptosis independent of nuclear 35 
signaling 
In early 2008 Marchetti et al made a huge breakthrough in 
understanding the cytotoxicity of Lam-D while studying non-
small cell lung carcinoma (NSCLC) cells, which are typically 
resistant to apoptosis induced by standard chemotherapy. 40 
They observed that Lam-D did not trigger signs of nuclear 
apoptosis coupled to the nuclear translocation of apoptosis-
inducing factor (AIF) in the cells, yet it induced activation of 
Bax, mitochondrial release of cytochrome c and AIF, and 
activation of caspase-3.32 45 
 In 2009 Bailly, Marchetti et al. reported further and more 
extensive studies using various tumor cell lines, including 
several leukemia and carcinoma lines.5 Their results suggest 
that for all cell types tested, Lam-D exerts its cytotoxicity 
primarily by inducing mitochondrial apoptosis independently 50 
of nuclear signaling.5 This work not only contributes to 
deciphering the apoptotic pathways activated by Lam-D but 
also provides evidence that Lam-D is still active even if the 
classical apoptotic pathways are blocked in cancer cells (i.e. 
when p53 is null/mutated, Topo I is mutated, and/or Bcl-2 is 55 
overexpressed). 
 In 2010 the same research group ultimately identified direct 
induction of mitochondrial permeability transition (MPT), 
which leads to swelling and cytochrome c release, as the 
mechanism behind the pro-apoptotic function of Lam-D.7  60 
These results indicate that functional mitochondria are 
required for Lam D-induced apoptosis. Furthermore, 
inhibition of mitochondrial respiration is responsible for 
MPT-dependent apoptosis of cancer cells induced by Lam-D.7 
 The aforementioned findings open the path to new cancer 65 
therapy strategies that target mitochondria, thereby 
reinforcing the potential value of mitochondriophilic drugs for 
this indication. Given the problems posed by drug resistant 
cancer cells, targeting mitochondria may prove an effective 
approach, as long as Lam-D or a related drug is sufficiently 70 
selective in affecting exclusively the mitochondria of cancer 
cells.5,7,32 
 
A new target, the malate–aspartate shuttle 
The ability to isolate and study mitochondria has enabled 75 
several interesting metabolic studies. Nevertheless, 
conclusions based only on these kinds of studies should be 
evaluated with prudence. Furthermore, state-of-the-art 
techniques such as proton NMR-based metabolomics are 
demonstrating that whole cells can be studied directly. For 80 
example, Morvan et al.3 have applied proton NMR-based 
metabolomics to screen the effects of Lam-D and two other 
drugs (also natural marine products) in whole human MCF7 
breast cancer cells. They observed that Lam-D provoked a 
severe decrease in DNA content in the MCF7 cells after 24 h 85 
treatment, followed by apoptosis. Metabolite profiling of the 
cells revealed major biochemical disorders following 
treatment with Lam-D: namely, accumulation of aspartate, 
glutamate, and lactate, which suggests that Lam-D targets the 
malate–aspartate shuttle.  90 
 
Inhibition of protein kinases 
Maijer et al. have also identified a new molecular target of 
lamellarins.4 They reported that lamellarins inhibit several 
protein kinases relevant to cancer, including cyclin-dependent 95 
kinases, dual specificity tyrosine phosphorylation activated 
kinase 1A, casein kinase 1, glycogen synthase kinase-3 and 
PIM-1. They found a good correlation between inhibition of 
protein kinases by lamellarins and cell death. This suggests 
that specific kinases may contribute to these drugs’ 100 
cytotoxicity, and could be harnessed together with the drugs’ 
other bioactivities to achieve anti-tumor effects. Further 
studies in this area are needed. 
Conclusions and Future Trends 
The unique structures and biological activities of the 105 
lamellarins and related pyrrole-derived alkaloids have 
attracted significant synthetic efforts in recent years. Thus, 
elegant synthetic routes to these compounds or their key 
intermediates have been developed. Since 2008, Lam-G 
trimethyl ether has been synthesized using four novel 110 
strategies, in total yields ranging from 5% to 45%15-17, 24 
 This journal is © The Royal Society of Chemistry 2011 Med. Chem. Commun. 
These highly modular approaches can provide access to any 
member of the family; one need only choose the appropriately 
substituted and protected building blocks. Additionally, these 
chemistries have proven valuable for preparation of 
structurally simplified lamellarin analogs, affording sufficient 5 
quantities for SAR and other biological studies.  
 The initial SAR studies on lamellarins have provided the 
first evidence that an OH group at C10 position is important 
for biological activity.27 Latter work demonstrated the 
importance of the C8=C9 double bond, and confirmed the 10 
importance of the OH groups at C3 and C11. To date, Lam-D, 
X, ε, M and N, and dehydro-Lam-J are the most potent anti-
tumor compounds of this family. 
 Further SAR studies of the 1-dearyl Lam-D analogs 
synthesized by Iwao et al.8 could provide useful data and a 15 
more thorough overview on structural simplification of the 
parent compound.  
 Incorporation of polar groups onto the core to facilitate 
further H-bonding interactions, as well as ionizable groups to 
enhance the solubility, can yield improved lamellarin analogs. 20 
For example, aza-Lam-D11, which contains one more H-bond 
donor than the parent compound; several PEG analogs of 
Lam-D (15, 16, 18, and 20) analogs;12 and a peptide 
bioconjugate of Lam-D (21)13 have shown enhanced 
bioactivity and physicochemical properties relative to the 25 
parent compound.  
 Future medicinal chemistry efforts should be addressed to 
provide derivatives and bioconjugates with greater specificity 
for biological targets. Given that Lam-D has been shown to 
inhibit the nuclear enzyme Topo I, medicinal chemists should 30 
prioritize achieving nuclear transport and release of this drug, 
and creating analogs able to cross the nuclear membrane on 
their own. Researchers should also explore if and how 
chemical modifications in the form of new lamellarin analogs 
could lead to improved or distinct mitochondrial/nuclear 35 
pathways of action. 
 Lastly, direct targeting of mitochondria by Lam-D can 
circumvent the drug resistance often encountered in tumor 
cells. Thus, Lam-D constitutes a new pro-apoptotic agent that 
may bypass certain forms of apoptosis resistance.5 40 
 Further studies can contribute to a better understanding of 
the mechanism of lamellarins and their analogs, and will be 
beneficial for the ongoing pharmacological optimization of 
this class of compounds. 
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